Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01688713 : Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Inclusion Criteria:

- Histological or cytologic diagnosis of NSCLC

- Patients with disease progression after local treatment(WBRT and/or SRS) combined
with Icotinib treatment.

- Patients with EGFR mutation or the lesions that remains stable for more than 3 months
after local treatment(WBRT and/or SRS) combined with Icotinib treatment.

- ECOG performance status 0-2

- Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)

- Expected survival of greater than 3 months

- Age: 18-75 years

- The patients with key organs maintenance of basic function: Hemoglobin ? 9g/dL,
White Blood Cell ? 3×109/L, Neutrophil count ? 1.5×109/L, platelets ? 80×109/L, total
bilirubin < 1.5 times of the upper normal values, Alanine transaminase (ALT) and
aspartate transaminase (AST) < 2.5 of the upper normal values, the serum creatinine <
1.5 times of the upper normal values

- Signed informed consent document on file.

Exclusion Criteria:

- Brain metastasis without local treatment before

- Patients without the treatment of Icotinib before or the therapeutic time less than 3

- More than 3 extracranial organs have metastatic lesions

- The patient with other type malignant tumors before

- The patient with fertility capacity, but without contraceptive application
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557